## CAH: Cardinal Health, Inc. - XLV: Healthcare

### Executive Summary

No thesis match: MRS_20 -2.2% below STRENGTH zone (4.0-10.0%); PEG 1.89 fails VALUE criteria (<1.0). Stock is in no-man's land without clear edge. Caution: momentum weakening (-8.8% MRS).

- **Horizon:** N/A - no position
- **Risk Profile:** N/A - avoiding
- **Stop Type:** Fixed 2xATR ($196.33)
- **If Wrong:** N/A - wait for clearer setup
- **Invalidation:** MRS_20 falling below -5% or breaking key support

### News

- **Articles:** 7
- **Sentiment:** Bullish (Bullish: 3, Bearish: 0)

**1. What Recent Specialty Pharma Moves Mean for Cardinal Health’s Stock Valuation**
- Source: Simply Wall Street | 20251202T193227 | Bullish | Relevance: 98%
- This article analyzes Cardinal Health's stock valuation following its expansion into specialty pharmaceuticals, highlighting its strong year-to-date performance and five-year growth. Using discounted cash flow (DCF) and price-to-earnings (PE) ratio analyses, the article suggests the stock is currently undervalued by 55% based on DCF and about right based on its PE ratio, particularly when considering Simply Wall St's proprietary Fair Ratio. The piece also introduces "Narratives" as a dynamic tool for investors to assess the company's future prospects and fair value.

**2. What Recent Specialty Pharma Moves Mean for Cardinal Health’s Stock Valuation**
- Source: Simply Wall Street | 20251202T193655 | Somewhat-Bullish | Relevance: 98%
- This article analyzes Cardinal Health's (NYSE:CAH) stock valuation following its expansion into specialty pharmaceuticals. The company's stock has seen significant growth, with a 76.2% year-to-date increase. Using discounted cash flow (DCF) analysis, Simply Wall St suggests Cardinal Health is undervalued by 55.0%, while its P/E ratio indicates it is "about right" given its financial profile and potential.

**3. Zacks.com featured highlights include Life Time, Cardinal Health, LeMaitre Vascular and Flowserve**
- Source: Yahoo Finance | 20251202T150200 | Bullish | Relevance: 98%
- Zacks.com highlights four stocks—Life Time, Cardinal Health, LeMaitre Vascular, and Flowserve—possessing high interest coverage ratios, signaling strong financial stability for investors heading into 2026. The article explains the importance of the interest coverage ratio as a critical indicator of a company's ability to meet financial obligations amid market uncertainties. Each highlighted company's recent performance metrics and Zacks Rank are provided, advocating for deeper financial evaluation beyond just headline figures.

**4. CAH SEC Filings - Cardinal Health Inc 10-K, 10-Q, 8-K Forms**
- Source: Stock Titan | 20251201T182131 | Neutral | Relevance: 98%
- This page provides an overview of Cardinal Health (CAH) SEC filings, including 10-K, 10-Q, and 8-K forms, with AI-powered summaries and real-time alerts for insider transactions. Recent filings detail performance-based share awards to key executives, a Form S-3 shelf prospectus, and fiscal year 2025 financial results showing increased operating earnings despite a revenue dip. The company also announced an acquisition and year-end results reporting.

**5. What Recent Specialty Pharma Moves Mean for Cardinal Health’s Stock Valuation**
- Source: Simply Wall Street | 20251202T193648 | Bullish | Relevance: 97%
- This article analyzes Cardinal Health's stock valuation following its expansion into specialty pharmaceuticals. Using Discounted Cash Flow analysis, the article suggests CAH is undervalued by 55%, with an intrinsic value of $461.80 per share. While its P/E ratio of 31x is slightly above the healthcare industry average, the article concludes that the valuation is "about right" given the company's financial profile and future potential, especially when considering its proprietary Fair Ratio.

### Analyst Activity

**Target Signal:** NEUTRAL (Raises: 0, Lowers: 0)

| Date | Firm | Target | Prior | Change |
|------|------|--------|-------|--------|
| 2025-12-09 | Barclays | $243 | $0 | 0% |

**Rating Changes:**

| Date | Firm | Action | Grade |
|------|------|--------|-------|
| 2025-12-09 | Barclays | init | Overweight |

### Insider Activity (90 days)

| Metric | Value |
|--------|-------|
| Direction | **NET_SELLING** |
| Buys | 11 ($0.00M) |
| Sells | 5 ($0.41M) |

### Institutional Ownership

| Metric | Value |
|--------|-------|
| Total Ownership | 46.4% |
| Smart Money | **BULLISH** |
| Net Flow | 0.0% |
| Buying/Selling | 7 / 3 |

**Top Holders:**
- Blackrock Inc.: 13.2% (+3.0%)
- Vanguard Group Inc: 13.0% (+0.8%)
- State Street Corpora: 5.2% (-3.0%)
- Geode Capital Manage: 2.7% (+1.5%)
- Wellington Managemen: 2.4% (+153.2%)

### Key Risks

1. Momentum deterioration: MRS_20 falling (-8.8% 5d) with bearish MACD, trend may be turning.
2. Market regime shift could impact momentum names disproportionately.
3. Sector rotation risk if leadership changes from current market theme.

### Catalysts

- AI/machine learning initiatives could drive multiple expansion if executed.
- Broader market risk-on sentiment could lift quality names.

### Fundamentals

PEG ratio 1.89 elevated, pricing in significant growth expectations. Institutional flow bullish (7 buying vs 3 selling).

| Metric | Value |
|--------|-------|
| Market Cap | $47.1B |
| Beta | 0.64 |
| 52W Range | $114.60 - $214.93 |
| Short Interest | 3.1% |

| Valuation | Value |
|-----------|-------|
| PEG Ratio | 1.89 |
| Forward P/E | 18.5 |
| Current P/E | 20.9 |
| YoY Growth | 12.8% |
| EPS Direction | STABLE |

### Technicals

MRS_20 deteriorating from 6.6% to -2.2% (-8.8% in 5 days), indicating relative weakness vs NASDAQ. Below STRENGTH zone by 6.2pp (needs >4.0% for momentum thesis). Long-term uptrend intact (above SMA200 at 1.32x) but short-term weakness (below SMA20). MACD histogram bearish (-1.68), momentum weakening.

| Metric | Value | Signal |
|--------|-------|--------|
| MRS_20 | -2.19% (CS: 33) | Weak |
| RSI_14 | 64.1 | Neutral |
| MACD Histogram | -1.68 | Bearish |
| vs SMA20 | 0.995x | Below |
| vs SMA50 | 1.148x | Above |
| vs SMA200 | 1.324x | Above |

### Decision

- **Verdict:** AVOID
- **Thesis:** NEUTRAL

### Trade Setup

- **Entry:** $205.13
- **Stop Loss:** $196.33 (4.3% risk)
- **Target:** $213.93 (R:R method)
- **Risk/Reward:** 1.00:1
- **Target Reasoning:** NEUTRAL thesis targets 1.0x risk/reward based on historical edge

### Position Sizing

- **Shares:** 113
- **Position Value:** $23,179.69
- **Portfolio %:** 23.18%
- **Risk Dollars:** $1,000.00
- **Risk Per Trade:** 1.00%
- **Modifiers:** L1 100% | L2 100% | Combined 1.00x

### Market Context

| Layer | Signal | Modifier |
|-------|--------|----------|
| L1 Macro | NORMAL (MEDIUM) | 1.00x |
| L2 Sector | NEUTRAL (Zone E) | 1.00x |

*NORMAL regime with moderate improvement trajectory. VIX compression from 20.5 to 16.6 over 5 days signals declining fear, while 47% breadth shows narrow but recovering participation. Fed meeting in 6 days creates near-term uncertainty, but AI sector momentum and improving technical setups support selective positioning.*

### Earnings

**Next:** 2026-01-29 (Est: $2.30)

| Quarter | Est | Actual | Surprise |
|---------|-----|--------|----------|
| 2025Q3 | $2.17 | $2.55 | +17.3% |
| 2025Q2 | $2.03 | $2.08 | +2.4% |
| 2025Q1 | $2.15 | $2.35 | +9.4% |
| 2024Q4 | $1.76 | $1.93 | +9.4% |

---
*RULE-based L3 | 2026-01-06 16:36 | MRS_20*